Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
Google Scholar
Siegel, R. L. et al. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10–45 (2025).
Google Scholar
White, M. C. et al. Age and cancer risk: a potentially modifiable relationship. Am. J. Prev. Med. 46, S7–S15 (2014).
Google Scholar
Lopez-Otin, C. et al. Meta-hallmarks of aging and cancer. Cell Metab. 35, 12–35 (2023).
Google Scholar
Lopez-Gil, L., Pascual-Ahuir, A. & Proft, M. Genomic instability and epigenetic changes during aging. Int. J. Mol. Sci. 24, 14279 (2023).
Google Scholar
Amorim, J. A. et al. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat. Rev. Endocrinol. 18, 243–258 (2022).
Google Scholar
Haran, J. P. & McCormick, B. A. Aging, frailty, and the microbiome-how dysbiosis influences human aging and disease. Gastroenterology 160, 507–523 (2021).
Google Scholar
Vilchez, D., Saez, I. & Dillin, A. The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat. Commun. 5, 5659 (2014).
Google Scholar
Li, X. et al. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct. Target Ther. 8, 239 (2023).
Google Scholar
Singhal, A., Li, B. T. & O’Reilly, E. M. Targeting KRAS in cancer. Nat. Med. 30, 969–983 (2024).
Google Scholar
Grothey, A., Fakih, M. & Tabernero, J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann. Oncol. 32, 959–967 (2021).
Google Scholar
Cooper, A. J., Sequist, L. V. & Lin, J. J. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat. Rev. Clin. Oncol. 19, 499–514 (2022).
Google Scholar
Raghav, K. P. S. & Moasser, M. M. Molecular pathways and mechanisms of HER2 in cancer therapy. Clin. Cancer Res. 29, 2351–2361 (2023).
Google Scholar
Hu, J. et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J. Hematol. Oncol. 14, 157 (2021).
Google Scholar
Christine, A., Park, M. K., Song, S. J. & Song, M. S. The equilibrium of tumor suppression: DUBs as active regulators of PTEN. Exp. Mol. Med. 54, 1814–1821 (2022).
Google Scholar
Zhang, L. & Shay, J. W. Multiple roles of APC and its therapeutic implications in colorectal cancer. J. Natl. Cancer Inst. 109, djw332 (2017).
Google Scholar
Li, S. et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J. Clin. Oncol. 40, 1529–1541 (2022).
Google Scholar
Dowty, J. G. et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum. Mutat. 34, 490–497 (2013).
Google Scholar
Chen, X. et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 13, 974 (2022).
Google Scholar
Thomas, A. F., Kelly, G. L. & Strasser, A. Of the many cellular responses activated by TP53, which ones are critical for tumour suppression? Cell Death Differ. 29, 961–971 (2022).
Google Scholar
Feng, Z. et al. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc. Natl. Acad. Sci. USA. 104, 16633–16638 (2007.
Google Scholar
Richardson, R. B. p53 mutations associated with aging-related rise in cancer incidence rates. Cell Cycle 12, 2468–2478 (2013).
Google Scholar
Lu, C. et al. The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. J. Natl. Cancer Inst. 109, djw283 (2017).
Google Scholar
de Lima Camillo, L. P. et al. Histone mark age of human tissues and cell types. Sci. Adv. 11, eadk9373 (2025).
Google Scholar
Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 14, R115 (2013).
Google Scholar
Lex, K. et al. Telomere shortening produces an inflammatory environment that increases tumor incidence in zebrafish. Proc. Natl. Acad. Sci. USA. 117, 15066–15074 (2020).
Google Scholar
Shay, J. W. & Wright, W. E. Role of telomeres and telomerase in cancer. Semin. Cancer Biol. 21, 349–353 (2011).
Google Scholar
Risques, R. A. et al. Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology 135, 410–418 (2008).
Google Scholar
Plentz, R. R. et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 40, 80–86 (2004).
Google Scholar
Franceschi, C. et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y Acad. Sci. 908, 244–254 (2000).
Google Scholar
Coppe, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010).
Google Scholar
Ragonnaud, E. & Biragyn, A. Gut microbiota as the key controllers of “healthy” aging of elderly people. Immun. Ageing 18, 2 (2021).
Google Scholar
Xu, X., Pang, Y. & Fan, X. Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduct. Target Ther. 10, 190 (2025).
Google Scholar
Liu, Z. et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct. Target Ther. 8, 200 (2023).
Google Scholar
Kanimozhi, N. V. & Sukumar, M. Aging through the lens of the gut microbiome: challenges and therapeutic opportunities. Arch. Gerontol. Geriatr. 2, 100142 (2025).
Qu, R. et al. Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer. Adv. Sci. 10, e2205563 (2023).
Google Scholar
Noor Akbar, N. A. K., Muhammad, J. S. & Siddiqui, R. The role of gut microbiome in cancer genesis and cancer prevention. Health Sci. Rev. 2, 100010 (2022).
Loeb, L. A., Wallace, D. C. & Martin, G. M. The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations. Proc. Natl. Acad. Sci. USA. 102, 18769–18770 (2005).
Google Scholar
Maldonado, E., Morales-Pison, S., Urbina, F. & Solari, A. Aging hallmarks and the role of oxidative stress. Antioxidants 12, 651 (2023).
Google Scholar
Li, H. S. et al. HIF-1alpha protects against oxidative stress by directly targeting mitochondria. Redox Biol. 25, 101109 (2019).
Google Scholar
Chang, S. T. et al. Age-dependent immune profile in healthy individuals: an original study, systematic review and meta-analysis. Immun. Ageing 21, 75 (2024).
Google Scholar
Nassour, J. et al. Telomere-to-mitochondria signalling by ZBP1 mediates replicative crisis. Nature 614, 767–773 (2023).
Google Scholar
Guth, M. Stem cell exhaustion as a hallmark of aging. J. Cell Sci. Regenerat. Med. 1, 20–26 (2025).
Niu, X. et al. Autophagy in cancer development, immune evasion, and drug resistance. Drug Resist. Updat 78, 101170 (2025).
Google Scholar
Colucci, M. et al. Senescence in cancer. Cancer Cell. 43, 1204–1226 (2025).
Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614–636 (1965).
Google Scholar
Varela, E. & Blasco, M. A. 2009 nobel prize in physiology or medicine: telomeres and telomerase. Oncogene 29, 1561–1565 (2010).
Google Scholar
Shay, J. W. Role of telomeres and telomerase in aging and cancer. Cancer Discov. 6, 584–593 (2016).
Google Scholar
Oh, J., Lee, Y. D. & Wagers, A. J. Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nat. Med. 20, 870–880 (2014).
Google Scholar
Fraifeld, V. E. & Rattan, S. I. S. Stem cells in ageing and longevity: a new section in Biogerontology. Biogerontology 26, 69 (2025).
Google Scholar
Yucel, A. D. & Gladyshev, V. N. The long and winding road of reprogramming-induced rejuvenation. Nat. Commun. 15, 1941 (2024).
Google Scholar
Feng, Y., He, D., Yao, Z. & Klionsky, D. J. The machinery of macroautophagy. Cell Res. 24, 24–41 (2014).
Google Scholar
Nieto-Torres, J. L. & Hansen, M. Macroautophagy and aging: The impact of cellular recycling on health and longevity. Mol. Asp. Med. 82, 101020 (2021).
Google Scholar
Li, X., He, S. & Ma, B. Autophagy and autophagy-related proteins in cancer. Mol. Cancer 19, 12 (2020).
Google Scholar
Short, S., Fielder, E., Miwa, S. & von Zglinicki, T. Senolytics and senostatics as adjuvant tumour therapy. EBioMedicine 41, 683–692 (2019).
Google Scholar
Johnson, S. C. Nutrient sensing, signaling and ageing: the role of IGF-1 and mTOR in ageing and age-related disease. Subcell. Biochem. 90, 49–97 (2018).
Google Scholar
Viola, C. M. et al. Structural conservation of insulin/IGF signalling axis at the insulin receptors level in Drosophila and humans. Nat. Commun. 14, 6271 (2023).
Google Scholar
Johnson, T. E. Increased life-span of age-1 mutants in Caenorhabditis elegans and lower Gompertz rate of aging. Science 249, 908–912 (1990).
Google Scholar
Paradis, S. et al. A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans. Genes Dev. 13, 1438–1452 (1999).
Google Scholar
Holzenberger, M. et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421, 182–187 (2003).
Google Scholar
Levina, A., Fleming, K. D., Burke, J. E. & Leonard, T. A. Activation of the essential kinase PDK1 by phosphoinositide-driven trans-autophosphorylation. Nat. Commun. 13, 1874 (2022).
Google Scholar
Martins, R., Lithgow, G. J. & Link, W. Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell 15, 196–207 (2016).
Google Scholar
Inoki, K. et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648–657 (2002).
Google Scholar
Fan, Z. et al. Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence. Exp. Gerontol. 186, 112359 (2024).
Google Scholar
Martin-Montalvo, A. et al. Metformin improves healthspan and lifespan in mice. Nat. Commun. 4, 2192 (2013).
Google Scholar
Guan, G., Chen, Y. & Dong, Y. Unraveling the AMPK-SIRT1-FOXO pathway: the in-depth analysis and breakthrough prospects of oxidative stress-induced diseases. Antioxidants 14, 70 (2025).
Google Scholar
Glaviano, A. et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138 (2023).
Google Scholar
Mannick, J. B. & Lamming, D. W. Targeting the biology of aging with mTOR inhibitors. Nat. Aging 3, 642–660 (2023).
Google Scholar
Valmori, D. et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J. Immunol. 177, 944–949 (2006).
Google Scholar
Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392–395 (2009).
Google Scholar
Cuervo, A. M. et al. Autophagy and aging: the importance of maintaining “clean” cells. Autophagy 1, 131–140 (2005).
Google Scholar
Wang, Y. et al. Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. Biochem. Biophys. Res. Commun. 434, 352–356 (2013).
Google Scholar
Wang, R. et al. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism. Aging Cell 16, 564–574 (2017).
Google Scholar
Yousefzadeh, M. J. et al. An aged immune system drives senescence and ageing of solid organs. Nature 594, 100–105 (2021).
Google Scholar
Chen, C., Liu, Y., Liu, Y. & Zheng, P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci. Signal 2, ra75 (2009).
Google Scholar
Mannick, J. B. et al. mTOR inhibition improves immune function in the elderly. Sci. Transl. Med. 6, 268ra179 (2014).
Google Scholar
Mannick, J. B. et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci. Transl. Med. 10, eaaq1564 (2018).
Google Scholar
Mannick, J. B. et al. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. Lancet Healthy Longev. 2, e250–e262 (2021).
Google Scholar
Wang, P., Mak, V. C. & Cheung, L. W. Drugging IGF-1R in cancer: new insights and emerging opportunities. Genes Dis. 10, 199–211 (2023).
Google Scholar
Law, J. H. et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68, 10238–10246 (2008).
Google Scholar
Dale, O. T. et al. IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer. Carcinogenesis 36, 648–655 (2015).
Google Scholar
Arafeh, R. & Samuels, Y. PIK3CA in cancer: the past 30 years. Semin. Cancer Biol. 59, 36–49 (2019).
Google Scholar
Andre, F. et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann. Oncol. 32, 208–217 (2021).
Google Scholar
Eberlein, C. et al. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br. J. Cancer 130, 1377–1387 (2024).
Google Scholar
Kwitkowski, V. E. et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15, 428–435 (2010).
Google Scholar
Dodd, K. M. et al. mTORC1 drives HIF-1alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34, 2239–2250 (2015).
Google Scholar
Lee, D. J. W., Hodzic Kuerec, A. & Maier, A. B. Targeting ageing with rapamycin and its derivatives in humans: a systematic review. Lancet Healthy Longev. 5, e152–e162 (2024).
Google Scholar
Hedges, C. P. et al. Dietary supplementation of clinically utilized PI3K p110alpha inhibitor extends the lifespan of male and female mice. Nat. Aging 3, 162–172 (2023).
Google Scholar
Medoro, A. et al. Targeting Senescence, Oxidative Stress, And Inflammation: Quercetin-based Strategies For Ocular Diseases In Older Adults. Clin. Inter. Aging 20, 791–813 (2025).
Google Scholar
Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. Nat. Med. 24, 1246–1256 (2018).
Google Scholar
Rauf, A. et al. Anticancer potential of quercetin: a comprehensive review. Phytother. Res. 32, 2109–2130 (2018).
Google Scholar
Tomou, E. M. et al. Recent advances in nanoformulations for quercetin delivery. Pharmaceutics 15, 1656 (2023).
Google Scholar
Herzig, S. & Shaw, R. J. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat. Rev. Mol. Cell Biol. 19, 121–135 (2018).
Google Scholar
Greer, E. L. et al. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr. Biol. 17, 1646–1656 (2007).
Google Scholar
Ge, Y. et al. Role of AMPK mediated pathways in autophagy and aging. Biochimie 195, 100–113 (2022).
Google Scholar
Canto, C. et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458, 1056–1060 (2009).
Google Scholar
Wu, W. et al. Effect of exercise and oral niacinamide mononucleotide on improving mitochondrial autophagy in Alzheimer’s disease. Nutrients 15, 2851 (2023).
Google Scholar
Abu Shelbayeh, O., Arroum, T., Morris, S. & Busch, K. B. PGC-1alpha is a master regulator of mitochondrial lifecycle and ROS stress response. Antioxidants 12, 1075 (2023).
Google Scholar
Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107–120 (2006).
Google Scholar
Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650–1653 (2006).
Google Scholar
Crighton, D. et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126, 121–134 (2006).
Google Scholar
Zhu, Y. & Prives, C. p53 and metabolism: the GAMT connection. Mol. Cell 36, 351–352 (2009).
Google Scholar
Li, T. et al. Targeting AMP-activated protein kinase in aging-related cardiovascular diseases. Aging Dis. 11, 967–977 (2020).
Google Scholar
Grabowska, W., Sikora, E. & Bielak-Zmijewska, A. Sirtuins, a promising target in slowing down the ageing process. Biogerontology 18, 447–476 (2017).
Google Scholar
Conlon, N. J. The role of NAD+ in regenerative medicine. Plast. Reconstr. Surg. 150, 41S–48S (2022).
Google Scholar
Wiernsperger, N. F. & Bailey, C. J. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 58, 75–82 (1999).
Google Scholar
Yang, Y. et al. Metformin decelerates aging clock in male monkeys. Cell 187, 6358–6378.e6329 (2024).
Google Scholar
Abou Zaki, R. & El-Osta, A. Metformin: decelerates biomarkers of aging clocks. Signal Transduct. Target Ther. 9, 319 (2024).
Google Scholar
Pifferi, F. et al. Resveratrol does not mimic the positive effects of calorie restriction on lifespan in Microcebus murinus. Commun. Biol. 8, 331 (2025).
Google Scholar
Yi, L. et al. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience 45, 29–43 (2023).
Google Scholar
Hemminki, A. et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184–187 (1998).
Google Scholar
Shaw, R. J. et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA. 101, 3329–3335 (2004).
Google Scholar
Shaw, R. J. et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91–99 (2004).
Google Scholar
Inoki, K., Li, Y., Xu, T. & Guan, K. L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829–1834 (2003).
Google Scholar
Hara, K. et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177–189 (2002).
Google Scholar
Kim, J., Kundu, M., Viollet, B. & Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132–141 (2011).
Google Scholar
Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
Google Scholar
Faubert, B. et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 17, 113–124 (2013).
Google Scholar
Carmeliet, P. et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485–490 (1998).
Google Scholar
Dreute, J., Pfisterer, M. & Schmitz, M. L. A reductionist perspective on HIF-1alpha’s role in cell proliferation under non-hypoxic conditions. Biochim. Biophys. Acta Mol. Cell Res. 1871, 119683 (2024).
Google Scholar
Jones, R. G. et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283–293 (2005).
Google Scholar
Park, H. U. et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol. Cancer Ther. 8, 733–741 (2009).
Google Scholar
Eichner, L. J. et al. Genetic analysis reveals AMPK is required to support tumor growth in murine Kras-dependent lung cancer models. Cell Metab. 29, 285–302 e287 (2019).
Google Scholar
Zadra, G. et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol. Med. 6, 519–538 (2014).
Google Scholar
Reczek, C. R. et al. Metformin targets mitochondrial complex I to lower blood glucose levels. Sci. Adv. 10, eads5466 (2024).
Google Scholar
Hu, D. et al. Metformin: a potential candidate for targeting aging mechanisms. Aging Dis. 12, 480–493 (2021).
Google Scholar
Zhu, L. et al. Metformin as anticancer agent and adjuvant in cancer combination therapy: current progress and future prospect. Transl. Oncol. 44, 101945 (2024).
Google Scholar
Wen, K. C. et al. Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer. J. Ovarian Res. 13, 95 (2020).
Google Scholar
Serageldin, M. A. et al. The effect of metformin on chemotherapy-induced toxicities in non-diabetic breast cancer patients: a randomised controlled study. Drug Saf. 46, 587–599 (2023).
Google Scholar
Kordes, S. et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 16, 839–847 (2015).
Google Scholar
Jetha, K. et al. Unveiling resveratrol’s potential: navigating the landscape of autoimmune diseases. Clin. Tradit. Med. Pharm. 5, 200145 (2024).
Google Scholar
Price, N. L. et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15, 675–690 (2012).
Google Scholar
Xia, Y. et al. Resveratrol activates autophagy and protects from UVA-induced photoaging in human skin fibroblasts and the skin of male mice by regulating the AMPK pathway. Biogerontology 25, 649–664 (2024).
Google Scholar
Bhattacharya, S., Darjatmoko, S. R. & Polans, A. S. Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB. Melanoma Res. 21, 180–187 (2011).
Google Scholar
Kim, Y. N. et al. Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis. Exp. Mol. Med. 49, e296 (2017).
Google Scholar
Silk, N. et al. The effects of resveratrol on prostate cancer through targeting the tumor microenvironment. J. Xenobiot. 11, 16–32 (2021).
Google Scholar
Brockmueller, A. et al. Resveratrol as sensitizer in colorectal cancer plasticity. Cancer Metastasis Rev. 43, 55–85 (2024).
Google Scholar
Jiang, H. et al. Resveratrol inhibits pancreatic cancer proliferation and metastasis by depleting senescent tumor-associated fibroblasts. World J. Gastrointest. Oncol. 16, 3980–3993 (2024).
Google Scholar
Xie, C. et al. Resveratrol suppresses lung cancer by targeting cancer stem-like cells and regulating tumor microenvironment. J. Nutr. Biochem. 112, 109211 (2023).
Google Scholar
Luo, B. et al. Resveratrol amplifies the anti-tumor effect of alpha-PD-1 by altering the intestinal microbiome and PGD2 content. Gut Microbes 17, 2447821 (2025).
Google Scholar
Walle, T. et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377–1382 (2004).
Google Scholar
Chai, Y., Zhou, Y., Zhang, K. & Shao, P. Resveratrol nanoparticles coated by metal-polyphenols supramolecular enhance antioxidant activity and long-term stability of dietary gel. Food Chem. 465, 141987 (2025).
Google Scholar
Luo, X. et al. Development of phospholipid complex loaded self-microemulsifying drug delivery system to improve the oral bioavailability of resveratrol. Nanomedicine 16, 721–739 (2021).
Google Scholar
Grau, L., Soucek, R. & Pujol, M. D. Resveratrol derivatives: Synthesis and their biological activities. Eur. J. Med. Chem. 246, 114962 (2023).
Google Scholar
Jiang, Y. et al. NAD(+) supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling. Oncogene 42, 808–824 (2023).
Google Scholar
Zhou, L. et al. Downregulation of miR-182-5p by NFIB promotes NAD+ salvage synthesis in colorectal cancer by targeting NAMPT. Commun. Biol. 6, 775 (2023).
Google Scholar
Lombard, D. B. et al. DNA repair, genome stability, and aging. Cell 120, 497–512 (2005).
Google Scholar
Paull, T. T. Mechanisms of ATM Activation. Annu. Rev. Biochem. 84, 711–738 (2015).
Google Scholar
Bakkenist, C. J. & Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499–506 (2003).
Google Scholar
McKinnon, P. J. ATM and ataxia telangiectasia. EMBO Rep. 5, 772–776 (2004).
Google Scholar
Qian, M. et al. Boosting ATM activity alleviates aging and extends lifespan in a mouse model of progeria. Elife 7, e34836 (2018).
Google Scholar
Lee, S. S. et al. ATM kinase is required for telomere elongation in mouse and human cells. Cell Rep. 13, 1623–1632 (2015).
Google Scholar
Kang, H. T. et al. Chemical screening identifies ATM as a target for alleviating senescence. Nat. Chem. Biol. 13, 616–623 (2017).
Google Scholar
Kuk, M. U. et al. Alleviation of senescence via ATM inhibition in accelerated aging models. Mol. Cells 42, 210–217 (2019).
Google Scholar
Ruzankina, Y. et al. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell 1, 113–126 (2007).
Google Scholar
Pennarun, G. et al. ATR contributes to telomere maintenance in human cells. Nucleic Acids Res. 38, 2955–2963 (2010).
Google Scholar
Feringa, F. M. et al. Persistent repair intermediates induce senescence. Nat. Commun. 9, 3923 (2018).
Google Scholar
Moulder, D. E. et al. The roles of p53 in mitochondrial dynamics and cancer metabolism: the pendulum between survival and death in breast cancer? Cancers 10, 189 (2018).
Google Scholar
Rodier, F., Campisi, J. & Bhaumik, D. Two faces of p53: aging and tumor suppression. Nucleic Acids Res. 35, 7475–7484 (2007).
Google Scholar
Dumble, M. et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 109, 1736–1742 (2007).
Google Scholar
Tyner, S. D. et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45–53 (2002).
Google Scholar
Maier, B. et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306–319 (2004).
Google Scholar
Wu, D. & Prives, C. Relevance of the p53-MDM2 axis to aging. Cell Death Differ. 25, 169–179 (2018).
Google Scholar
Ohkusu-Tsukada, K., Tsukada, T. & Isobe, K. Accelerated development and aging of the immune system in p53-deficient mice. J. Immunol. 163, 1966–1972 (1999).
Google Scholar
Cortez, M. A. et al. PDL1 Regulation by p53 via miR-34. J. Natl. Cancer Inst. 108, djv303 (2016).
Google Scholar
Rodier, F. et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11, 973–979 (2009).
Google Scholar
Ghosh, A. et al. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. J. Clin. Invest 132, e148141 (2022).
Google Scholar
Li, L. et al. A unique role for p53 in the regulation of M2 macrophage polarization. Cell Death Differ. 22, 1081–1093 (2015).
Google Scholar
Johnson, N. A. et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114, 2273–2279 (2009).
Google Scholar
Kostic, V. et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277, 559–562 (1997).
Google Scholar
Martin, N., Popgeorgiev, N., Ichim, G. & Bernard, D. BCL-2 proteins in senescence: beyond a simple target for senolysis? Nat. Rev. Mol. Cell Biol. 24, 517–518 (2023).
Google Scholar
Elena-Real, C. A. et al. Cytochrome c speeds up caspase cascade activation by blocking 14-3-3epsilon-dependent Apaf-1 inhibition. Cell Death Dis. 9, 365 (2018).
Google Scholar
Los, M. et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol. Biol. Cell 13, 978–988 (2002).
Google Scholar
Kieronska-Rudek, A. et al. The PARP inhibitor olaparib promotes senescence in murine macrophages. Geroscience 48, 755–775 (2025).
Bai, P. et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13, 461–468 (2011).
Google Scholar
Guo, S. et al. Muscle PARP1 inhibition extends lifespan through AMPKalpha PARylation and activation in Drosophila. Proc. Natl. Acad. Sci. USA. 120, e2213857120 (2023).
Google Scholar
Nwosu, G. O., Ross, D. M., Powell, J. A. & Pitson, S. M. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis. 15, 413 (2024).
Google Scholar
Lee, J. B. et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood 138, 234–245 (2021).
Google Scholar
Kim, G. et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res. 21, 4257–4261 (2015).
Google Scholar
Balasubramaniam, S. et al. FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin. Cancer Res. 23, 7165–7170 (2017).
Google Scholar
Ison, G. et al. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Clin. Cancer Res. 24, 4066–4071 (2018).
Google Scholar
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
Google Scholar
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
Google Scholar
Chen, H. Z., Tsai, S. Y. & Leone, G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9, 785–797 (2009).
Google Scholar
Wang, X. et al. Recent progress of CDK4/6 inhibitors’ current practice in breast cancer. Cancer Gene Ther. 31, 1283–1291 (2024).
Google Scholar
Damian, S. et al. Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC). J. Clin. Oncol. 43, 5514–5514 (2025).
Google Scholar
Juric, D. et al. BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC). J. Clin. Oncol. 42, 1056–1056 (2024).
Google Scholar
Riches, L. C. et al. Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically. Mol. Cancer Ther. 19, 13–25 (2020).
Google Scholar
Besse, B. et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat. Med. 30, 716–729 (2024).
Google Scholar
Giudice, E. et al. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nat. Commun. 15, 2805 (2024).
Google Scholar
Sanjiv, K. et al. Cancer-specific synthetic lethality between ATR and CHK1 kinase activities. Cell Rep. 14, 298–309 (2016).
Google Scholar
Ma, C. X. et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J. Clin. Invest 122, 1541–1552 (2012).
Google Scholar
Wang, W. et al. MDM2 inhibitors for cancer therapy: the past, present, and future. Pharm. Rev. 76, 414–453 (2024).
Google Scholar
Saleh, M. N. et al. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin. Cancer Res. 27, 5236–5247 (2021).
Google Scholar
Wang, Z. et al. The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death Differ. 30, 1033–1046 (2023).
Google Scholar
Park, H. et al. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open 7, 100573 (2022).
Google Scholar
Thangaretnam, K. et al. WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials. Crit. Rev. Oncol. Hematol. 211, 104710 (2025).
Google Scholar
Fu, S. et al. Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. J. Clin. Oncol. 41, 1725–1734 (2023).
Google Scholar
Hernandez-Silva, D. et al. Senescence-independent anti-inflammatory activity of the senolytic drugs dasatinib, navitoclax, and venetoclax in zebrafish models of chronic inflammation. Int. J. Mol. Sci. 23, 10468 (2022).
Google Scholar
Mato, A. R. et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 103, 1511–1517 (2018).
Google Scholar
Mackay, H. et al. Exactis-03: a phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer. J. Clin. Oncol. 41, TPS5623–TPS5623 (2023).
Google Scholar
Hayden, M. S. & Ghosh, S. Shared principles in NF-kappaB signaling. Cell 132, 344–362 (2008).
Google Scholar
Salminen, A. et al. Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res. Rev. 7, 83–105 (2008).
Google Scholar
Mao, H., Zhao, X. & Sun, S. C. NF-kappaB in inflammation and cancer. Cell Mol. Immunol. 22, 811–839 (2025).
Google Scholar
Hinz, M. & Scheidereit, C. The IkappaB kinase complex in NF-kappaB regulation and beyond. EMBO Rep. 15, 46–61 (2014).
Google Scholar
Miyamoto, S. Nuclear initiated NF-kappaB signaling: NEMO and ATM take center stage. Cell Res. 21, 116–130 (2011).
Google Scholar
Seeler, J. S. & Dejean, A. SUMO and the robustness of cancer. Nat. Rev. Cancer 17, 184–197 (2017).
Google Scholar
Squarize, C. H. et al. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8, 733–746 (2006).
Google Scholar
Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234–248 (2018).
Google Scholar
Freudlsperger, C. et al. TGF-beta and NF-kappaB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene 32, 1549–1559 (2013).
Google Scholar
Tichy, E. D. et al. Persistent NF-kappaB activation in muscle stem cells induces proliferation-independent telomere shortening. Cell Rep. 35, 109098 (2021).
Google Scholar
Catheline, S. E. et al. IKKbeta-NF-kappaB signaling in adult chondrocytes promotes the onset of age-related osteoarthritis in mice. Sci. Signal 14, eabf3535 (2021).
Google Scholar
Cai, D. & Han, J. J. Aging-associated lncRNAs are evolutionarily conserved and participate in NFkappaB signaling. Nat. Aging 1, 438–453 (2021).
Google Scholar
Coperchini, F. et al. Inflamm-ageing: How cytokines and nutrition shape the trajectory of ageing. Cytokine Growth Factor Rev. 82, 31–42 (2024).
Google Scholar
Ryu, S. et al. Genetic signature of human longevity in PKC and NF-kappaB signaling. Aging Cell 20, e13362 (2021).
Google Scholar
Zhang, L. et al. Novel small molecule inhibition of IKK/NF-kappaB activation reduces markers of senescence and improves healthspan in mouse models of aging. Aging Cell 20, e13486 (2021).
Google Scholar
Squarzoni, S. et al. Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice. Aging Cell 20, e13285 (2021).
Google Scholar
Prasnikar, E., Borisek, J. & Perdih, A. Senescent cells as promising targets to tackle age-related diseases. Ageing Res. Rev. 66, 101251 (2021).
Google Scholar
Caiado, F. & Manz, M. G. IL-1 in aging and pathologies of hematopoietic stem cells. Blood 144, 368–377 (2024).
Google Scholar
Mitchell, C. A. et al. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat. Cell Biol. 25, 30–41 (2023).
Google Scholar
Nallasamy, P. et al. Sulforaphane reduces vascular inflammation in mice and prevents TNF-alpha-induced monocyte adhesion to primary endothelial cells through interfering with the NF-kappaB pathway. J. Nutr. Biochem. 25, 824–833 (2014).
Google Scholar
Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519–550 (2009).
Google Scholar
Kelley, N., Jeltema, D., Duan, Y. & He, Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 20, 3328 (2019).
Google Scholar
Darakhshan, S. & Pour, A. B. Tranilast: a review of its therapeutic applications. Pharm. Res. 91, 15–28 (2015).
Google Scholar
He, Y. et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530, 354–357 (2016).
Google Scholar
Huang, Y. et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol. Med. 10, e8689 (2018).
Google Scholar
Marin-Aguilar, F. et al. NLRP3 inflammasome inhibition by MCC950 in aged mice improves health via enhanced autophagy and PPARalpha activity. J. Gerontol. A Biol. Sci. Med. Sci. 75, 1457–1464 (2020).
Google Scholar
Han, S. et al. Inhibiting NLRP3 inflammasome activation by CY-09 helps to restore cerebral glucose metabolism in 3xTg-AD mice. Antioxidants 12, 722 (2023).
Google Scholar
Flores, J. et al. Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat. Commun. 11, 4571 (2020).
Google Scholar
Wang, L., Chen, P. & Xiao, W. beta-hydroxybutyrate as an anti-aging metabolite. Nutrients 13, 3420 (2021).
Google Scholar
Liang, Y. B. et al. VX-765 attenuates secondary damage and beta-amyloid accumulation in ipsilateral thalamus after experimental stroke in rats. Exp. Neurol. 385, 115097 (2025).
Google Scholar
Roberts, M. N. et al. A ketogenic diet extends longevity and healthspan in adult mice. Cell Metab. 26, 539–546.e535 (2017).
Google Scholar
Han, Y. M., Ramprasath, T. & Zou, M. H. beta-hydroxybutyrate and its metabolic effects on age-associated pathology. Exp. Mol. Med. 52, 548–555 (2020).
Google Scholar
Gangemi, S. et al. Increased circulating Interleukin-18 levels in centenarians with no signs of vascular disease: another paradox of longevity? Exp. Gerontol. 38, 669–672 (2003).
Google Scholar
Novick, D. IL-18 and IL-18BP: a unique dyad in health and disease. Int. J. Mol. Sci. 25, 13505 (2024).
Google Scholar
Griveau, A. et al. The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes. Aging Cell 19, e13122 (2020).
Google Scholar
Jiang, C. et al. Administration of AG490 decreases the senescence of umbilical cord-mesenchymal stem cells and promotes the cytotherapeutic effect in liver fibrosis. Cell Death Discov. 9, 273 (2023).
Google Scholar
Zhang, C. et al. Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2/STAT3 pathway. J. Cancer Res. Clin. Oncol. 150, 168 (2024).
Google Scholar
Yaqin, Z. et al. Resveratrol alleviates inflammatory bowel disease by inhibiting JAK2/STAT3 pathway activity via the reduction of O-GlcNAcylation of STAT3 in intestinal epithelial cells. Toxicol. Appl. Pharm. 484, 116882 (2024).
Google Scholar
Porro, C. et al. Curcumin Regulates Anti-inflammatory Responses by JAK/STAT/SOCS signaling pathway in BV-2 microglial cells. Biology 8, 51 (2019).
Google Scholar
Zukowski, E. et al. STAT3 modulates CD4(+) T mitochondrial dynamics and function in aging. Aging Cell 22, e13996 (2023).
Google Scholar
Zhou, D. et al. Increased production of TGF-beta and Il-6 by aged spleen cells. Immunol. Lett. 36, 7–11 (1993).
Google Scholar
Bhadra, R. et al. Intrinsic TGF-beta signaling promotes age-dependent CD8+ T cell polyfunctionality attrition. J. Clin. Invest. 124, 2441–2455 (2014).
Google Scholar
Zhang, Y., Alexander, P. B. & Wang, X. F. TGF-beta Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harb. Perspect. Biol. 9, a022145 (2017).
Google Scholar
Ren, L. L. et al. TGF-beta as a master regulator of aging-associated tissue fibrosis. Aging Dis. 14, 1633–1650 (2023).
Google Scholar
Marulanda, J. et al. Skeletal effects of bone-targeted TGFbeta inhibition in a mouse model of duchenne muscular dystrophy. Life 11, 791 (2021).
Google Scholar
Yan, X. et al. Smad7 protein interacts with receptor-regulated Smads (R-Smads) to inhibit transforming growth factor-beta (TGF-beta)/Smad signaling. J. Biol. Chem. 291, 382–392 (2016).
Google Scholar
Hu, M. et al. Smad7 attenuates TGF-beta-mediated aging-related hypofunction of submandibular glands. Exp. Biol. Med. 246, 1269–1273 (2021).
Google Scholar
Nong, J. et al. Verteporfin inhibits TGF-beta signaling by disrupting the Smad2/3-Smad4 interaction. Mol. Biol. Cell 35, ar95 (2024).
Google Scholar
Pakjoo, M. et al. Interplay between proteasome inhibitors and NF-kappaB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors. Cell Commun. Signal 22, 105 (2024).
Google Scholar
Prabhu, K. S. et al. Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans. Cell Death Discov. 10, 225 (2024).
Google Scholar
Perez-Galan, P. et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107, 257–264 (2006).
Google Scholar
Cillessen, S. A. et al. Bortezomib induces caspase-9-mediated apoptosis through activation of the BH3-only proteins Noxa, Bik and Puma in both ALK-positive and ALK-negative anaplastic large cell lymphoma cells. Blood 116, 2847–2847 (2010).
Google Scholar
Ridker, P. M. et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017).
Google Scholar
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Google Scholar
Davis, C. C., Shah, K. S. & Lechowicz, M. J. Clinical development of siltuximab. Curr. Oncol. Rep. 17, 29 (2015).
Google Scholar
Chen, R. & Chen, B. Siltuximab (CNTO 328): a promising option for human malignancies. Drug Des. Devel Ther. 9, 3455–3458 (2015).
Google Scholar
Le, R. Q. et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23, 943–947 (2018).
Google Scholar
Mascarenhas, J. & Hoffman, R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin. Cancer Res. 18, 3008–3014 (2012).
Google Scholar
Lahiri, T. et al. Mitochondrial STAT3 regulates antioxidant gene expression through complex I-derived NAD in triple negative breast cancer. Mol. Oncol. 15, 1432–1449 (2021).
Google Scholar
Genini, D. et al. Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. Proc. Natl. Acad. Sci. USA. 114, E4924–E4933 (2017.
Google Scholar
Formenti, S. C. et al. Focal irradiation and systemic TGFbeta blockade in metastatic breast cancer. Clin. Cancer Res. 24, 2493–2504 (2018).
Google Scholar
Melisi, D. et al. Safety and activity of the TGFbeta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J. Immunother. Cancer 9, e002068 (2021).
Google Scholar
Kelley, R. K. et al. A phase 2 study of galunisertib (TGF-beta1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clin. Transl. Gastroenterol. 10, e00056 (2019).
Google Scholar
Melisi, D. et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br. J. Cancer 119, 1208–1214 (2018).
Google Scholar
Wick, A. et al. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Invest. N. Drugs 38, 1570–1579 (2020).
Google Scholar
Dong, Z. et al. Cellular senescence and SASP in tumor progression and therapeutic opportunities. Mol. Cancer 23, 181 (2024).
Google Scholar
Wu, Q. J. et al. The sirtuin family in health and disease. Signal Transduct. Target Ther. 7, 402 (2022).
Google Scholar
Sauve, A. A. & Youn, D. Y. Sirtuins: NAD(+)-dependent deacetylase mechanism and regulation. Curr. Opin. Chem. Biol. 16, 535–543 (2012).
Google Scholar
Iqbal, T. & Nakagawa, T. The therapeutic perspective of NAD(+) precursors in age-related diseases. Biochem. Biophys. Res Commun. 702, 149590 (2024).
Google Scholar
Wei, Z. et al. Caloric restriction, Sirtuins, and cardiovascular diseases. Chin. Med. J. 137, 921–935 (2024).
Google Scholar
Fulco, M. et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev. Cell 14, 661–673 (2008).
Google Scholar
Thapa, R. et al. The role of sirtuin 1 in ageing and neurodegenerative disease: a molecular perspective. Ageing Res. Rev. 102, 102545 (2024).
Google Scholar
Jing, H. & Lin, H. Sirtuins in epigenetic regulation. Chem. Rev. 115, 2350–2375 (2015).
Google Scholar
Yang, Y. et al. Regulation of SIRT1 and Its Roles in Inflammation. Front. Immunol. 13, 831168 (2022).
Google Scholar
Vaquero, A. et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 16, 93–105 (2004).
Google Scholar
Wan, Y. Z. et al. SIRT1-mediated epigenetic downregulation of plasminogen activator inhibitor-1 prevents vascular endothelial replicative senescence. Aging Cell 13, 890–899 (2014).
Google Scholar
Zhang, Y. et al. SIRT1 alleviates isoniazid-induced hepatocyte injury by reducing histone acetylation in the IL-6 promoter region. Int. Immunopharmacol. 67, 348–355 (2019).
Google Scholar
Yang, Y., Zhu, G., Yang, L. & Yang, Y. Targeting CD24 as a novel immunotherapy for solid cancers. Cell Commun. Signal 21, 312 (2023).
Google Scholar
Wang, T. W. et al. SIRT1-mediated expression of CD24 and epigenetic suppression of novel tumor suppressor miR-1185-1 increases colorectal cancer stemness. Cancer Res. 80, 5257–5269 (2020).
Google Scholar
Kowluru, R. A., Santos, J. M. & Zhong, Q. Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 55, 5653–5660 (2014).
Google Scholar
Brunet, A. et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011–2015 (2004).
Google Scholar
Wu, Q. et al. Effect of autophagy regulated by Sirt1/FoxO1 pathway on the release of factors promoting thrombosis from vascular endothelial cells. Int. J. Mol. Sci. 20, 4132 (2019).
Google Scholar
Saxena, S., Anand, S. K., Sharma, A. & Kakkar, P. Involvement of Sirt1-FoxO3a-Bnip3 axis and autophagy mediated mitochondrial turnover in according protection to hyperglycemic NRK-52E cells by Berberine. Toxicol. Vitr. 100, 105916 (2024).
Google Scholar
Yao, J. et al. CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma. Autophagy 18, 1879–1897 (2022).
Google Scholar
Wei, X. et al. SIRT1-mediated deacetylation of FOXO3 enhances mitophagy and drives hormone resistance in endometrial cancer. Mol. Med. 30, 147 (2024).
Google Scholar
Canto, C. & Auwerx, J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipido. 20, 98–105 (2009).
Google Scholar
D’Errico, I. et al. Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc. Natl. Acad. Sci. USA. 108, 6603–6608 (2011).
Google Scholar
Dan, L. et al. PGC1alpha promotes cholangiocarcinoma metastasis by upregulating PDHA1 and MPC1 expression to reverse the Warburg effect. Cell Death Dis. 9, 466 (2018).
Google Scholar
Do, M. T., Kim, H. G., Choi, J. H. & Jeong, H. G. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1alpha/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic. Biol. Med. 74, 21–34 (2014).
Google Scholar
de Gregorio, E., Colell, A., Morales, A. & Mari, M. Relevance of SIRT1-NF-kappaB axis as therapeutic target to ameliorate inflammation in liver disease. Int. J. Mol. Sci. 21, 3858 (2020).
Google Scholar
Ong, A. L. C. & Ramasamy, T. S. Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming. Ageing Res. Rev. 43, 64–80 (2018).
Google Scholar
Ryu, D. R. et al. Sirt1-hypoxia-inducible factor-1alpha interaction is a key mediator of tubulointerstitial damage in the aged kidney. Aging Cell 18, e12904 (2019).
Google Scholar
Joo, H. Y. et al. SIRT1 deacetylates and stabilizes hypoxia-inducible factor-1alpha (HIF-1alpha) via direct interactions during hypoxia. Biochem. Biophys. Res. Commun. 462, 294–300 (2015).
Google Scholar
Vaquero, A. et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 20, 1256–1261 (2006).
Google Scholar
Pun, R. et al. BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer. Semin. Cancer Biol. 106-107, 201–216 (2024).
Google Scholar
Skoge, R. H., Dolle, C. & Ziegler, M. Regulation of SIRT2-dependent alpha-tubulin deacetylation by cellular NAD levels. DNA Repair. 23, 33–38 (2014).
Google Scholar
Serrano, L. et al. The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes Dev. 27, 639–653 (2013).
Google Scholar
Li, H. & Cai, Z. SIRT3 regulates mitochondrial biogenesis in aging-related diseases. J. Biomed. Res. 37, 77–88 (2022).
Google Scholar
Olmos, Y. et al. SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a/PGC-1α complex. Antioxid. Redox Signal 19, 1507–1521 (2013).
Google Scholar
Yao, H. et al. SIRT1 protects against cigarette smoke-induced lung oxidative stress via a FOXO3-dependent mechanism. Am. J. Physiol. Lung Cell Mol. Physiol. 306, L816–L828 (2014).
Google Scholar
Chalkiadaki, A. & Guarente, L. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat. Rev. Endocrinol. 8, 287–296 (2012).
Google Scholar
Ouyang, S. et al. The double-edged sword of SIRT3 in cancer and its therapeutic applications. Front. Pharm. 13, 871560 (2022).
Google Scholar
Tennen, R. I. & Chua, K. F. Chromatin regulation and genome maintenance by mammalian SIRT6. Trends Biochem. Sci. 36, 39–46 (2011).
Google Scholar
Kawahara, T. L. et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 136, 62–74 (2009).
Google Scholar
Michishita, E. et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452, 492–496 (2008).
Google Scholar
Onn, L. et al. SIRT6 is a DNA double-strand break sensor. Elife 9, e51636 (2020).
Google Scholar
Zhong, L. et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140, 280–293 (2010).
Google Scholar
Ford, E. et al. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 20, 1075–1080 (2006).
Google Scholar
Kumari, P., Tarighi, S., Braun, T. & Ianni, A. SIRT7 acts as a guardian of cellular integrity by controlling nucleolar and extra-nucleolar functions. Genes 12, 1361 (2021).
Google Scholar
Paredes, S. et al. The epigenetic regulator SIRT7 guards against mammalian cellular senescence induced by ribosomal DNA instability. J. Biol. Chem. 293, 11242–11250 (2018).
Google Scholar
Barber, M. F. et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 487, 114–118 (2012).
Google Scholar
Ianni, A. et al. SIRT7-dependent deacetylation of NPM promotes p53 stabilization following UV-induced genotoxic stress. Proc. Natl. Acad. Sci. USA. 118, e2015339118 (2021).
Google Scholar
Freeberg, K. A. et al. Dietary supplementation with NAD+-boosting compounds in humans: current knowledge and future directions. J. Gerontol. A Biol. Sci. Med. Sci. 78, 2435–2448 (2023).
Google Scholar
Damgaard, M. V. & Treebak, J. T. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci. Adv. 9, eadi4862 (2023).
Google Scholar
Song, Q. et al. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update. Adv. Nutr. 14, 1416–1435 (2023).
Google Scholar
Dellinger, R. W. et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech. Dis. 3, 17 (2017).
Google Scholar
Jensen, J. B. et al. A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals. JCI Insight 7, e158314 (2022).
Google Scholar
Ciccone, L. et al. Resveratrol-like compounds as SIRT1 activators. Int. J. Mol. Sci. 23, 15105 (2022).
Google Scholar
Gong, H. et al. miR-146a impedes the anti-aging effect of AMPK via NAMPT suppression and NAD(+)/SIRT inactivation. Signal Transduct. Target Ther. 7, 66 (2022).
Google Scholar
Sun, F. et al. Effects of dietary management combined with exercise interventions on type 2 diabetes: a pilot before-after study in the same patient. Clin. Tradit. Med. Pharm. 5, 200133 (2024).
Google Scholar
Qiu, Y. et al. Exercise sustains the hallmarks of health. J. Sport Health Sci. 12, 8–35 (2023).
Google Scholar
Zhao, L.-K. et al. The burden of pancreatic cancer from Asia in 2022 and predictions to 2050 according to GLOBOCAN estimates. Gut Med. 1, 18–29 (2025).
Google Scholar
Urruticoechea, A. et al. Recent advances in cancer therapy: an overview. Curr. Pharm. Des. 16, 3–10 (2010).
Google Scholar
Kelly, C. M., Power, D. G. & Lichtman, S. M. Targeted therapy in older patients with solid tumors. J. Clin. Oncol. 32, 2635–2646 (2014).
Google Scholar
D’Souza, A. et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol. Blood Marrow Transpl. 26, e177–e182 (2020).
Google Scholar
Burstein, H. J. et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J. Clin. Oncol. 39, 3959–3977 (2021).
Google Scholar
Agostinis, P. et al. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 61, 250–281 (2011).
Google Scholar
Al-Refaie, W. B. et al. Major cancer surgery in the elderly: results from the American College of Surgeons National Surgical Quality Improvement Program. Ann. Surg. 251, 311–318 (2010).
Google Scholar
Repetto, L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J. Support Oncol. 1, 18–24 (2003).
Google Scholar
Grubey, J. S., Raji, Y., Duke, W. S. & Terris, D. J. Outpatient thyroidectomy is safe in the elderly and super-elderly. Laryngoscope 128, 290–294 (2018).
Google Scholar
Gomez-Millan, J. Radiation therapy in the elderly: more side effects and complications? Crit. Rev. Oncol. Hematol. 71, 70–78 (2009).
Google Scholar
Daste, A. et al. Targeted therapy and elderly people: a review. Eur. J. Cancer 69, 199–215 (2016).
Google Scholar
Cupit-Link, M. C., Arora, M., Wood, W. A. & Hashmi, S. K. Relationship between aging and hematopoietic cell transplantation. Biol. Blood Marrow Transpl. 24, 1965–1970 (2018).
Google Scholar
Riseberg, D. Treating elderly patients with hormone receptor-positive advanced breast cancer. Clin. Med. Insights Oncol. 9, 65–73 (2015).
Google Scholar
Pepping, R. M. C., Portielje, J. E. A., van de Water, W. & de Glas, N. A. Primary endocrine therapy in older women with breast cancer. Curr. Geriatr. Rep. 6, 239–246 (2017).
Google Scholar
Carriero, S. et al. Ablative therapies for breast cancer: state of art. Technol. Cancer Res. Treat. 22, 15330338231157193 (2023).
Google Scholar
Nishikawa, M. et al. Assessment of photodynamic therapy as a salvage treatment for local failure after chemoradiotherapy or radiotherapy for esophageal cancer in patients aged 80 years or older. DEN Open 3, e167 (2023).
Google Scholar
Hamaker, M. et al. Geriatric assessment in the management of older patients with cancer – a systematic review (update). J. Geriatr. Oncol. 13, 761–777 (2022).
Google Scholar
Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458 (2014).
Google Scholar
Bai, R. et al. Mechanisms of cancer resistance to immunotherapy. Front. Oncol. 10, 1290 (2020).
Google Scholar
Perez-Ruiz, E. et al. Cancer immunotherapy resistance based on immune checkpoints inhibitors: targets, biomarkers, and remedies. Drug Resist. Updat 53, 100718 (2020).
Google Scholar
Padron, A. et al. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. Exp. Gerontol. 105, 146–154 (2018).
Google Scholar
Surh, C. D., Boyman, O., Purton, J. F. & Sprent, J. Homeostasis of memory T cells. Immunol. Rev. 211, 154–163 (2006).
Google Scholar
Bansal-Pakala, P. & Croft, M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J. Immunol. 169, 5005–5009 (2002).
Google Scholar
Fulop, T. et al. Intracellular signalling pathways: targets to reverse immunosenescence. Clin. Exp. Immunol. 187, 35–43 (2017).
Google Scholar
Salminen, A. Increased immunosuppression impairs tissue homeostasis with aging and age-related diseases. J. Mol. Med. 99, 1–20 (2021).
Google Scholar
Sceneay, J. et al. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer. Cancer Discov. 9, 1208–1227 (2019).
Google Scholar
Betof, A. S. et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist 22, 963–971 (2017).
Google Scholar
Kugel, C. H. 3rd et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin. Cancer Res. 24, 5347–5356 (2018).
Google Scholar
Jain, V. et al. Association of age with efficacy of immunotherapy in metastatic melanoma. Oncologist 25, e381–e385 (2020).
Google Scholar
Wu, Q. et al. Correlation between patients’ age and cancer immunotherapy efficacy. Oncoimmunology 8, e1568810 (2019).
Google Scholar
Lian, J., Yue, Y., Yu, W. & Zhang, Y. Immunosenescence: a key player in cancer development. J. Hematol. Oncol. 13, 151 (2020).
Google Scholar
Pawelec, G. Age and immunity: what is “immunosenescence”? Exp. Gerontol. 105, 4–9 (2018).
Google Scholar
Ferrara, R. et al. Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy. Clin. Cancer Res. 27, 492–503 (2021).
Google Scholar
Liu, X. et al. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy. Sci. Transl. Med. 13, eaaz6314 (2021).
Google Scholar
Liu, X. et al. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy. J. Immunother. Cancer 10, e005020 (2022).
Google Scholar
Pawelec, G., Lustgarten, J., Ruby, C. & Gravekamp, C. Impact of aging on cancer immunity and immunotherapy. Cancer Immunol. Immunother. 58, 1907–1908 (2009).
Google Scholar
Zhang, Y. et al. Reconstructing the immunosenescence core pathway reveals global characteristics in pan-cancer. Cancer Immunol. Immunother. 72, 3693–3705 (2023).
Google Scholar
Pellegrino, M. et al. Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target. Front. Immunol. 15, 1356321 (2024).
Google Scholar
Zhang, Y. et al. Pan-cancer analysis of IGF-1 and IGF-1R as potential prognostic biomarkers and immunotherapy targets. Front. Oncol. 11, 755341 (2021).
Google Scholar
Ma, D. et al. Identification of IGF1R mutation as a novel predictor of efficacious immunotherapy in melanoma. J. Transl. Med. 20, 172 (2022).
Google Scholar
Salminen, A., Kaarniranta, K. & Kauppinen, A. Insulin/IGF-1 signaling promotes immunosuppression via the STAT3 pathway: impact on the aging process and age-related diseases. Inflamm. Res. 70, 1043–1061 (2021).
Google Scholar
O’Donnell, J. S., Massi, D., Teng, M. W. L. & Mandala, M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin. Cancer Biol. 48, 91–103 (2018).
Google Scholar
Beziaud, L. et al. Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. Int. J. Cancer 143, 3008–3018 (2018).
Google Scholar
Langdon, S. et al. Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology 7, e1458810 (2018).
Google Scholar
Cao, G. et al. mTOR inhibition potentiates cytotoxicity of Vgamma4 gammadelta T cells via up-regulating NKG2D and TNF-alpha. J. Leukoc. Biol. 100, 1181–1189 (2016).
Google Scholar
Batey, M. A. et al. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol. Cancer Ther. 12, 959–967 (2013).
Google Scholar
Petersen, A. J., Rimkus, S. A. & Wassarman, D. A. ATM kinase inhibition in glial cells activates the innate immune response and causes neurodegeneration in Drosophila. Proc. Natl. Acad. Sci. USA. 109, E656–E664 (2012).
Google Scholar
Hartlova, A. et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 42, 332–343 (2015).
Google Scholar
Zhang, Q. et al. Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. Cancer Res. 79, 3940–3951 (2019).
Google Scholar
Hu, M. et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. J. Clin. Invest. 131, e139333 (2021).
Google Scholar
Yu, D., Wang, H., Liu, H. & Xu, R. Liposomal ATM siRNA delivery for enhancing triple-negaitive breast cancer immune checkpoint blockade therapy. J. Biomater. Appl. 37, 1835–1846 (2023).
Google Scholar
Xiao, Y. et al. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat. Commun. 13, 758 (2022).
Google Scholar
Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).
Google Scholar
Kim, S. S. et al. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma. Int. J. Cancer 145, 2535–2546 (2019).
Google Scholar
Dong, Z. Y. et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 23, 3012–3024 (2017).
Google Scholar
Sun, H. et al. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. EBioMedicine 60, 102990 (2020).
Google Scholar
Kim, J. Y. et al. TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors. Cancer Med. 12, 12438–12451 (2023).
Google Scholar
Kohlhapp, F. J. et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 11, 68–79 (2021).
Google Scholar
Liu, P. et al. The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation. Cell Death Differ. 30, 2447–2451 (2023).
Google Scholar
Liu, L. et al. BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion. Mol. Cancer 21, 59 (2022).
Google Scholar
Mathew, R. et al. The BCL-2-selective inhibitor venetoclax spares activated T-cells during anti-tumor immunity. Blood. 132, 3704 (2018).
Hayden, M. S. & Ghosh, S. NF-kappaB in immunobiology. Cell Res. 21, 223–244 (2011).
Google Scholar
Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-kappaB signaling in inflammation. Signal Transduct. Target Ther. 2, 17023 (2017).
Google Scholar
Evaristo, C. et al. Cutting edge: engineering active IKKbeta in T cells drives tumor rejection. J. Immunol. 196, 2933–2938 (2016).
Google Scholar
Giordano, M. et al. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc. Natl. Acad. Sci. USA. 111, 11115–11120 (2014).
Google Scholar
Luo, F., Song, X., Zhang, Y. & Chu, Y. Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. Int. Immunopharmacol. 11, 1234–1240 (2011).
Google Scholar
Liu, D. et al. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer. Int. Immunopharmacol. 39, 265–272 (2016).
Google Scholar
Mukherjee, S. et al. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells. J. Exp. Clin. Cancer Res. 37, 168 (2018).
Google Scholar
Lim, S. O. et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell 30, 925–939 (2016).
Google Scholar
Wang, X. et al. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells. Anticancer Drugs 25, 282–288 (2014).
Google Scholar
Thirukkumaran, C. M. et al. Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood Adv. 3, 797–812 (2019).
Google Scholar
Richardson, P. G. et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl. J. Med. 387, 132–147 (2022).
Google Scholar
Zou, S. et al. Targeting STAT3 in cancer immunotherapy. Mol. Cancer 19, 145 (2020).
Google Scholar
Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48–54 (2004).
Google Scholar
Herrmann, A. et al. CTLA4 promotes Tyk2-STAT3-dependent B-cell oncogenicity. Cancer Res. 77, 5118–5128 (2017).
Google Scholar
Hsu, P. et al. IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J. Immunol. 195, 3665–3674 (2015).
Google Scholar
Keremu, A., Aimaiti, A., Liang, Z. & Zou, X. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines. Cancer Chemother. Pharm. 83, 255–264 (2019).
Google Scholar
Song, J., Wang, J., Tian, S. & Li, H. Discovery of STAT3 inhibitors: recent advances and future perspectives. Curr. Med. Chem. 30, 1824–1847 (2023).
Google Scholar
Kim, T. W. et al. Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma. Mol. Ther. Oncolytics 26, 1–14 (2022).
Google Scholar
Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).
Google Scholar
Li, X. et al. The yin-yang of DNA damage response: roles in tumorigenesis and cellular senescence. Int. J. Mol. Sci. 14, 2431–2448 (2013).
Google Scholar
Wolf, P., Schoeniger, A. & Edlich, F. Pro-apoptotic complexes of BAX and BAK on the outer mitochondrial membrane. Biochim. Biophys. Acta Mol. Cell Res. 1869, 119317 (2022).
Google Scholar
Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA. 92, 9363–9367 (1995).
Google Scholar
